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Introduction: Phenylketonuria (PKU) is an autosomal recessive disorder characterized by a deﬁciency in
phenylalanine (Phe) hydroxylase activity. Early diagnosis and continuous treatment with a low Phe diet
prevents severe neurological and cognitive impairment.
Aims: 1. Analyze how treatment adherence evolves through infancy, childhood, and early adolescence in
individuals with PKU. 2. Identify early signs of treatment discontinuation.
Methodology: This longitudinal, retrospective study included 75 children diagnosed through newborn screening,
ages 7 to 13 years. Data on blood Phe concentration, number of blood samples sent, proportion of samples with
Phe concentrations over the recommended range, and number of visits to the metabolism clinic were recorded.
Logistic regression analysis was used to identify the variables that predict treatment discontinuation before
13 years of age.
Results: A progressive increase in mean blood Phe concentrations with age was identiﬁed. The greatest increase
occurred between the ﬁrst and second years of life. By age ten, mean Phe blood concentration of the group was
above the recommended range. The proportion of samples with Phe concentrations over the recommended range
also increased with age, from an average of 13% during the ﬁrst year of life to 67% in early adolescence. Sixty-
eight percent of the children attended the outpatient clinic and sent samples from birth to the time of the study.
Individuals who discontinued follow-up showed signiﬁcantly higher mean blood Phe concentrations (360 vs.
220.9 μmol/L; p = 0.004) and the proportion of samples over the recommended range (37% vs. 12% p = 0.002)
was signiﬁcantly higher during the second year of life. Mean age for children who discontinued treatment was
5.5 years of age. Blood Phe concentration values at 12 to 23 months of age and at 6 to 8 years of age signiﬁcantly
predicted treatment discontinuation before 13 years of age.
Conclusion: Treatment adherence in PKU diminishes with age. Early signs of treatment discontinuation can be
identiﬁed during the second year of life, allowing preventive interventions in high risk groups.
1. Introduction
Phenylketonuria (PKU) is an autosomal recessive disorder charac-
terized by a deﬁciency in phenylalanine hydroxylase activity, causing
increased phenylalanine (Phe) plasma and tissue concentrations. Left
untreated, PKU leads to severe intellectual disability. Early diagnosis
and continuous treatment with a low Phe diet prevents severe
neurological and cognitive impairment in aﬀected individuals, with
the achievement of intelligence quotients (IQs) within the average
range, but lower than control groups [1–7].
Treatment for PKU requires avoidance of high protein foods, such as
all meats, dairy, nuts, beans, and eggs and allows for only measured
amounts of grains, fruits, and vegetables. A special formula provides the
necessary nutrients found in protein without the phenylalanine. The
diet is extremely restrictive and the formula has a strong taste and odor,
which makes adherence to treatment extremely challenging [8,9].
In a study of treatment adherence in 56 Brazilian PKU patients, in
which adherence was deﬁned by the median Phe concentration for a
12-month period, only 32.1% of the samples attained the targeted Phe
levels: for children< 13 years this was ≤360 μmol/L; for children
≥13 years, the target was ≤900 μmol/L [10].
Progressive deterioration in metabolic control has also been re-
ported with age. Data from a survey of 10 European centers with a total
of 1921 patients showed that at age one, the median blood Phe
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concentration was 175 μmol/L; between 1 and 3 years, the median was
230 μmol/L; between 4 and 10 years the median was 287 μmol/L;
between 11 and 16 years the median was 465 μmol/L; and over
16 years the median was 777 μmol/L. Also, the median percentage of
blood samples meeting guidelines tended to diminish with age [11].
Similar results were reported by Meli and Bianca [12]. In this
sample, blood Phe concentrations were greater than the recommended
value in none of the patients younger than 1 year of age, in 8% of the 1-
to 6-year-olds, 18% of the 6- to 10-year-olds, 40% of the 10- to 14-year-
olds, and 70% of those older than 14 years.
When trying to understand how compliance to treatment changes in
diﬀerent stages of life, what the underlying causes are, and the impact
of non-compliance to treatment in PKU, it must be understood that
there is no agreement regarding which compliance measures are most
important and how they should be deﬁned. As Mac Donald [8]
proposes, direct assessment of blood Phe concentration is perhaps the
best overall measure, but there is still no consensus regarding the
number of Phe concentrations that should be within target range over
time and the frequency or timing of the measure. Also, most studies of
compliance in PKU focus on short periods (12 to 24 months) and follow
the same patients over longer periods of time.
In Chile, the prevalence is 1/18,916 births for PKU and 1/10,198
births for mild hyperphenylalaninemia (mHPA). Since 1992, Chile has
had a national neonatal screening program for phenylketonuria that
covers 99% of newborns. Children with classical PKU (Phe≥20 mg/dL
[1200 μmol/L]), mild PKU (Phe 6 to 19 mg/dL [360 to 1190 μmol/L])
and also mHPA (Phe 2 to 6 mg/dL1[20 to 360 μmol/L]) enter a follow-
up program for hyperphenylalaninemia (HPA) at the Institute of
Nutrition and Food Technology (INTA), University of Chile national
referral center. The follow-up program for children with PKU and
mHPA includes regular measurements of Phe and tyrosine levels, as
well as specialized assessments by a multidisciplinary team of pedia-
tricians, nutritionists, neurologists, and psychologists. From diagnosis
to adulthood multiple resources are used in patient education, from
group workshops, written materials, individual/family education ses-
sions, apps, among others.
Phe concentrations were both home monitored (samples taken at
home and sent by mail) and monitored during clinical visits. Until 2010
the targeted blood Phe concentration of the Center was< 6 mg/dL
during the ﬁrst years of life and< 8 mg/dL (480 μmol/L) for patients
age 10 years or older. Currently, the targeted blood Phe concentrations
are≤4 mg/dL (240 μmol/L) during the ﬁrst year of life and< 6 mg/dL
(360 μmol/L) after that. Nutritional treatment should be maintained for
life. All PKU patients from birth to age 24 years have access through
government subsidy to Phe free formula at no charge.
The present study seeks to describe and understand how treatment
compliance changes through infancy, childhood, and early adolescence
in PKU patients. We also aim to identify early indicators of poor
treatment compliance and risk of treatment discontinuation that could
be addressed to prevent poor cognitive outcome in early-diagnosed
patients.
2. Subjects and methods
This longitudinal, retrospective study included all children diag-
nosed through newborn screening in Chile between February 2001 and
October 2008 (age 7 years to 13 years 11 months, median age:
11.4 years). Data on a total of 75 patients (33 females and 42 males)
with a mean age of diagnosis conﬁrmation of 15.8 days of life (range 2
to 45; SD = 7.3) and average Phe blood concentration of 18.8 mg/dL
(1138 μmol/L) (range 6 to 38.5 mg/dL; SD = 7.8) at diagnosis were
analyzed. Treatment of all patients was initiated immediately after
diagnostic conﬁrmation. All included patients received a protein-
restricted diet and had access to Phe-free formula at no cost, through
government subsidy. No patients were receiving sapropterin treatment.
Yearly mean Phe concentration, number of blood samples sent,
proportion of samples over the recommended range, and visits to the
outpatient clinic were recorded for all patients. Given the relevance of
early years on neurological development, data from the ﬁrst year of life
through age 4 years were analyzed separately in four groups, namely 0
to 11 months, 12 to 23 months, 24 to 35 months, and 36 to 48 months.
Data from 4 years of age onward were analyzed in two-year periods,
including 4 to 5 years and 11 months, 6 years to 7 years and 11 months,
8 years to 9 years and 11 months, 10 years to 11 years to 11 months,
and 12 years to 12 years and 11 months.
Patients' treatment discontinuation was deﬁned as no attendance to
the outpatient clinic in a two-year period and no blood samples sent in a
one-year period, both together.
Changes in the number of samples provided by the participants
across the diﬀerent assessment times were assessed with a repeated-
measures ANOVA, Greenhouse-Geisser corrections were applied when
sphericity assumptions were not met. Changes in blood Phe levels were
assessed with a Friedman's ANOVA, since the variables were not
normally distributed. Additional post hoc analyses were conducted
using Wilcoxon signed-rank tests with a Bonferroni correction applied.
A hierarchical regression analysis was conducted to explore the
prospective contribution of blood Phe levels measured across the
participants´ ﬁrst to seventh year of age to blood Phe levels at
8–10 years of age. Blood Phe levels measured at each assessment time
were entered separately into the equation to control for the inﬂuence of
earlier blood Phe levels. Results were tested against Bonferroni
corrected p values.
The Shapiro-Wilk test was used to verify normal distribution of the
data. Treatment adherence variables from individuals who did and did
not discontinue treatment before 13 years of age were compared using
Student's t-test. When normal distribution of a variable could not be
proven, the nonparametric Mann-Whitney test was used. Additionally,
child development and cognitive performance between groups was
compared by using the nonparametric Mann-Whitney test. It was
hypothesized that the participants in the group who discontinued
treatment before 13 years of age would have poorer treatment com-
pliance as expressed in all the measured variables. Therefore, signiﬁ-
cance was tested against 1-tailed p values.
A series of independent logistic regression analyses were conducted
to ascertain the eﬀect of the above mentioned treatment adherence
variables measured at each assessment time on the likelihood that
participants would discontinue treatment before 13 years of age. The
variables were entered into the equation using the Enter method. Data
were analyzed using SPSS 21.
3. Results
The results show a progressive increase in mean blood Phe
concentrations with age. A Friedman's ANOVA analysis showed a
statistically signiﬁcant diﬀerence in blood Phe levels measured at
diﬀerent assessment times, χ2(7) = 79.32, p = 0.000. Post hoc ana-
lyses with Wilcoxon signed-rank tests were conducted with a Bonferroni
correction applied, resulting in a signiﬁcance level set at p < 0.007. A
signiﬁcant increase in Phe levels was observed between the partici-
pant's ﬁrst and second year of life (Z =−3.869, p = 0.000) with an
increase of 1.1 mg/dL (66.1 μmol/L), and between the participants'
second and third year of life (Z =−2.756, p = 0.006). There were no
signiﬁcant diﬀerences between blood Phe levels measured at
36–48 months and at 4 years–5 years 11 months of age. However, there
was a statistically signiﬁcant increase in blood Phe levels between the
age ranges of 6–7 years 11 months of age and 8–9 years 11 months of
age (Z =−3.381, p = 0.001).
By age ten, the mean Phe blood concentration of the group was
above the recommended range (< 6 mg/dL) (Fig. 1).
As expected, the proportion of samples with Phe concentrations
over 6 mg/dL (360 μmol/L) also increased with age, rising from an
average of 13% during the ﬁrst year of life to 67% in early adolescence.
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However, between 12 years and 13 years 11 months of age only 6
participants were in the studied group (Table 1).
A hierarchical regression analysis showed that blood Phe levels from
the second to the seventh year of age made a signiﬁcant contribution to
blood Phe levels at 8–10 years of age. Detailed results of the contribu-
tion of individual predictors are in Table 2.
The mean number of samples sent also diminished signiﬁcantly in
the ﬁrst three years of life, (Table 1). A repeated-measures ANOVA
revealed that there were signiﬁcant changes in the number of samples
provided by the participants across the diﬀerent assessment times F
(1.19, 22.63) = 4.72. Contrasts revealed that number of samples
provided during the ﬁrst year of life (1–11 months of age) was larger
than those provided during the second year of life (12–23 months of
age) F(1, 19) = 75.31, p = 0.000. Similarly, the number of samples
provided during the second year of life was larger than during the third
year of life (24–35 months of age) F(1, 19) = 21.58, p = 0.000. No
other signiﬁcant diﬀerences were observed.
The number of patients with poor treatment compliance (deﬁned
as> 25% of samples> 6 mg/dL), increased with age. From age 1 to
10–12 years the percentage of patients with a proportion samples over
the recommended range increased from 14% to 76% (see Table 3).
During the ﬁrst three years of life, the proportion of patients with mean
Phe concentrations over the recommended range doubled each year.
Between ages four and six years, more than one-third of the patients'
mean Phe concentrations were over the recommended range. From age
8 years onward, more than half of the patients reported mean Phe
concentrations over the recommended range (see Table 3).
Regarding the number of visits to the outpatient clinic, during the
ﬁrst year of life, the mean number of visit was of 11.8 (range 2–20
visits; SD 4.2). During this period, the minimum number of recom-
mended visits was 12. In the second year of life, the mean number of
visit was 4.52 (range 0–11; SD 3.48). During this period the minimum
number of recommended visits was 4. In the following years the
number of visits continued to diminish. From ages 3 to 14, the
minimum number of recommended visits per year was 3. By age 10
to 11 years, the mean number of visits was of 1.08 visits per year (see
Table 3).
The number of patients sending an insuﬃcient number of blood
samples per year was 2% in the ﬁrst year of life (minimum of 17
samples per year). By puberty> 60% of the patients sent an insuﬃ-
cient number of samples (minimum of 12 samples per year) (Table 3).
3.1. Follow-up discontinuation
Of the 75 patients, 51 (68%) attended the outpatient clinic and sent
samples from birth to the end of the study period, regardless of
metabolic control. The mean full scale IQ (FSIQ) at school age of the
group that continued treatment was 93.7 ± 15.
Fifteen (20%) patients discontinued follow-up treatment, deﬁned as
no attendance at the outpatient clinic in a two-year period and no blood
samples sent in a one-year period. The average age of follow-up
discontinuation was 5.5 years, and half of these patients were between
ages 4 and 6 years when they ceased sending blood samples and
attending the outpatient clinic. In this group, IQ assessment data
Fig. 1. Mean blood Phe concentrations according to age period.
Table 1
Descriptive analysis of treatment adherence variables from 0 months to 13 years of age.
Age (years: y, m: months) Proportion of samples with Phe> 6 mg/dL (> 360 μmol/L) Mean blood samples sent per year Mean outpatient clinic visits per year
0–11 m (n = 73) 13% 29.0 11.8
12–23 m (n = 72) 20% 16.1 4.5
24–35 m (n = 73) 28% 12.6 3.5
36–48 m (n = 70) 31% 11.1 2.7
4 y–5 y 11 m (n = 67) 34% 10.8 2.0
6 y–7 y 11 m (n = 61) 42% 8.0 1.7
8 y–9 y 11 m (n = 42) 52% 8.0 1.3
10 y–11 y 11 m (n = 25) 52% 7.5 1.1
12 y–13 y 11 m (n = 6) 67% 6.4 0.9
Table 2
Summary of hierarchical regression analyses predicting blood Phe levels at 8–10 years of
age.
Model R2 Adj R2 F df Signiﬁcant contributors
Variable t Beta
1 0.03 0.01 1.28 (1,35)
2 0.19 0.14 4.22⁎ (2,34) Phe-2 2.65⁎ 0.49
3 0.32 0.26 5.59⁎⁎ (3,33) Phe-3 2.63⁎ 0.49
4 0.33 0.26 4.38⁎⁎ (4,32) Phe-3 2.04⁎ 0.42
5 0.40 0.31 4.52⁎⁎ (5,31)
6 0.42 0.32 4.0⁎⁎ (6,30)
7 0.60 0.51 6.90⁎⁎ (7,29) Phe-7 3.80⁎⁎ 0.75
Note. Phe-2 = Phe at 12–23 months of age, Phe-3 = Phe at 24–35 months of age, Phe-
5 = Phe at 4 years to 4 years 11 months of age, Phe-7 = Phe at 6 years to 7 years
11 months of age.
Predictors. Model 1: (constant), Phe at 1–11 months of age.
Model 2: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age.
Model 3: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age, Phe at
24–35 months of age.
Model 4: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age, Phe at
24–35 months of age, Phe at 3 years to 3 years 11 months.
Model 5: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age, Phe at
24–35 months of age, Phe at 3 years to 3 years 11 months, Phe at 4 years to 4 years
11 months.
Model 6: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age, Phe at
24–35 months of age, Phe at 3 years to 3 years 11 months, Phe at 4 years to 4 years
11 months, Phe at 5–6 years of age.
Model 7: (constant), Phe at 1–11 months of age, Phe at 12–23 months of age, Phe at
24–35 months of age, Phe at 3 years to 3 years 11 months, Phe at 4 years to 4 years
11 months, Phe at 5–6 years of age, Phe at 6–8 years of age.
⁎ p < 0.05.
⁎⁎ p < 0.01.
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obtained by age appropriate Wechsler Scale, were available for only 7
patients before discontinuation. Mean FSIQ was 86 ± 13, and only 3 of
the 6 patients preformed within the average range.
Five patients (7%) discontinued follow up, but later resumed. The
mean FSIQ in this group was 74 ± 13 and only 1 of the 5 patients
performed within the average range after follow-up resumption.
Four patients (5%) stopped attending outpatient clinic between ages
8 to 11 years of age, but continued to send blood samples. All four
children had performed within the average range with a mean FSIQ of
97.2 ± 11 prior to discontinuing attendance at the outpatient clinic.
To identify possible early signs that could suggest follow-up
discontinuation, the group of patients who discontinued follow up
(completely or partially) was compared to those who did not. During
the ﬁrst year of life, the proportion of samples over the recommended
range in the group to discontinue was 19% compared to 10% in the rest
of the patients, but this diﬀerence was not statistically signiﬁcant.
During the second year of life (between 12 and 23 months of age) the
group of patients to later discontinue showed signiﬁcantly higher mean
Phe blood concentration (5.96 mg/dL (360 μmol/L) compared to
3.65 mg/dL (220.1 μmol/L); U = 333.5, p = 0.004). And, 59% of the
children who later discontinued follow up, partially or completely,
presented mean Phe concentrations over the recommended range,
compared with only 6% of the remainder of the group. The proportion
of samples over the recommended range was signiﬁcantly higher in the
group to discontinue follow up, 37% vs. 12% (U = 210, p = 0.002)
during second year of life.
When comparing both groups during the third year of life, a
signiﬁcantly higher mean Phe blood concentration was noted in the
group to discontinue follow up (5.7 vs. 4.4 mg/dL (345 vs 266 μmol/L);
U = 397 p = 0.031) as well as a higher proportion of samples over the
recommended range (40% vs. 23% U= 319.5 p = 0.028). Also during
this period, the group that discontinued submitted fewer blood samples
(median 12 vs. 9; U = 338 p = 0.05).
Between ages 4 and 6 years, mean Phe concentrations were also
signiﬁcantly higher in the group that discontinued treatment (6.7 vs.
4.8 mg/dL U = 262, p = 0.005) as was the percentage of samples over
the recommended range (48% vs. 29%, U = 309.5, p = 0.031).
Logistic regression analyses included the following variables to
predict treatment discontinuation before 13 years of age: Phe levels,
Phe standard deviation, number of blood samples submitted, and
proportion of samples with Phe levels> 6 mg/dL at each assessment
time. Following multicollinearity analysis, the proportion of samples
with Phe levels> 6 mg/dL was removed from the analyses.
The logistic regression models identiﬁed variables from periods
between 12 and 23 months of age and 6 to 8 years of age as signiﬁcant.
Variables from age 12 to 23 months (χ2(3) = 13.689, p < 0.01)
explained 29% (Nagelkerke R2) of the variance in adherence to
treatment and correctly classiﬁed 75% of cases. Higher Phe levels were
associated with an increase in the likelihood of discontinuing treatment
before 13 years of age (OR = 1751; IC 95% 1109–2764; p = 0,016).
Similarly, the model including data from ages 6 to 8 years of age (χ2(3)
= 14.499, p < 0.01) explained 30.1% (Nagelkerke R2) of the variance
in adherence to treatment and correctly classiﬁed 77% of cases. Again,
for ages 6 to 8 years, higher Phe levels were associated with an
increased treatment discontinuation (OR = 1.682; IC 95%
1199–2358; p = 0,003).
4. Discussion
Since 1992, 216 early diagnosed phenylketonuria and 184 mild
hyperphenylalaninemia patients have entered a follow-up program for
PKU patients at the Laboratory of Genetic and Metabolic Diseases of
INTA, University of Chile.
Early diagnosis and nutritional treatment resulted in dramatic
improvement in the prognosis for patients with PKU in our group, as
in many other centers worldwide. Despite this success, medical
management of PKU is complex and challenging for the patients and
their parents. Many barriers have been described to treatment com-
pliance, such as access to specialized food, educational background,
family and social characteristics among others [8].
Although alternative therapies are now eﬀective in some patients
and are available in some countries, most patients continue to require
protein-restricted diets and Phe-free formula. Moreover, the targeted
Phe blood concentrations has progressively decreased and treatment is
now recommended to be maintained for life. Understanding how
treatment adherence changes as the child gets older is helpful in
developing age-appropriate strategies to promote health behaviors,
especially during critical periods even before suboptimal results are
identiﬁed.
When comparing our results to European countries it is possible to
see that the mean Phe concentrations we have reported are slightly
above the mean of 10 European centers, but still maintaining mean Phe
under 6 mg/dL until 8 years of age. For example, during the ﬁrst year of
life mean Phe concentrations of our group (3.2 mg/dL) are similar to
the ones reported in Turkey, The Netherlands, and Belgium. During
puberty, the mean Phe concentration of our group (6.9 mg/dL) are
similar to those in Belgium, higher than those in Italy and The
Netherlands; but lower than those in Denmark, Norway, Poland and
Turkey [13] (supplementary table). Also, when comparing our results to
results reported by [14] in a study that included 47 PKU patients age 6
to 18, from the United States, our group showed lower mean Phe
concentrations from ﬁrst years (year or years?) of life until age
10 years.
Harnett [15] studied metabolic control in a group of 33 PKU
patients in Canada during childhood. Good metabolic control was
deﬁned as> 60% of the samples being in the recommended range
(2–6 mg/dL [120–360 μmol/L]). Approximately 61% of the patients did
not meet good adherence criteria during the ﬁrst year of life. For our
group only 14% did not meet good adherence criteria (good compliance
deﬁned as ≥75% being in the recommended range). Our group also
showed a greater percentage of patients with a proportion of samples in
the recommended age between age 1 and 6 years, yet in the group
Table 3
Descriptive analysis of the proportion of patients to comply with treatment guidelines from 0 months to 13 years of age.
Age (years: y, m:
months)
Proportion of patients mean Phe> 6 mg/
dL (> 360 μmol/L)
Proportion of patients with> 25% of samples with
Phe 6 > mg/dL (> 360 μmol/L)
Proportion of patients with an insuﬃcient
number of yearly blood samples
0–11 m (n = 73) 7% 14% 2%
12–23 m (n = 72) 13% 28% 7%
24–35 m (n = 73) 26% 43% 19%
36–48 m (n = 70) 26% 49% 26%
4 y–5 y 11 m (n = 67) 34% 52% 42%
6 y–7 y 11 m (n = 61) 46% 66% 56%
8 y–9 y 11 m (n = 42) 55% 64% 60%
10 y–11 y 11 m
(n = 25)
60% 76% 60%
12 y–13 y 11 m (n = 6) 67% 100% 83%
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between 6 and 12 years of age, the results are similar to those in other
countries.
Regarding treatment discontinuation, when comparing our results
to recent reports on adherence in PKU patients, it was possible to
observe that in our group only 5% of the patients between 0 and 4 years
of age where lost to follow up, compared with 10% reported by Jureki
et al. [16] in patients in the United States. Between 5 and 12 years of
age, 15% percent of the patients in our group were lost to follow up,
compared with 12% reported in the mentioned study.
Our study demonstrated the possibility of identifying early signs of
treatment discontinuation during the ﬁrst years of life and the
importance of using diﬀerent indicators of treatment adherence simul-
taneously. Speciﬁcally it was possible to observe that during the ﬁrst
year of life children to later discontinue follow-up had a higher mean
Phe concentration and proportion of blood samples with Phe concen-
tration over the recommended range. Between 12 and 23 months of
age, these patients had signiﬁcantly higher mean Phe concentrations
and proportions of samples over the recommended range.
During the second year of life, submitting a diminished number of
blood samples might also be relevant. Overall, 64% of patients who had
an insuﬃcient number of blood samples sent (nine or fewer per year)
between 12 and 23 months of age later discontinued treatment.
However, our models showed that when more than one variable was
included in the analyses, we were able to more accurately predict which
children would discontinue treatment. Indicators included number of
samples, number of visits to outpatient clinic, as well as Phe levels and
variability in metabolic control. By considering multiple indicators, we
can better identify children and families who may need additional
support, education, or counseling. In addition, this allows for the
possibility of intervening early to increase treatment adherence before
cognitive functioning is aﬀected.
When analyzing the number of outpatient clinic visits, a limitation
of the study was not including data on the location where the child
lived. Location is relevant in this group since some of our most remote
patients live> 1000 miles from the clinic. For this reason, nutritional
counseling is frequently given by telephone. These data were not
included in the analysis.
Despite this limitation, the information presented in this article has
helped deﬁne a set of strategies implemented in our Center to promote
treatment adherence in our young PKU patients. One strategy has been
to focus on identifying early risk factors in the following areas: low
parental degree of understanding or acceptance of the condition,
insuﬃcient number of blood samples sent, no request for blood sample
results, elevated Phe blood concentration, insuﬃcient Phe free formula
intake, missing outpatient clinic visits and psychosocial risk factors.
When one or more of these areas are aﬀected in infants and
children, the patient is assigned to our high priority group. These cases
are addressed in a monthly meeting where a physician, nutritionist,
psychologist and social worker develop the most appropriate strategy to
support the patient and his/her family. Cases of older children with
very poor treatment compliance or who require social services protec-
tion due to severe parental neglect are also addressed in this way. In the
upcoming years, we intend to report on the long-term impact of these
strategies.
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